Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Brian I RiniJavid J MoslehiMarc BonacaManuela SchmidingerLaurence AlbigesToni K ChoueiriRobert J MotzerMichael B AtkinsJohn B A G HaanenMariangela MarianiJing WangSubramanian HariharanJames M G LarkinPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Patients with high baseline troponin T levels receiving ICI and VEGFR combinations may need to be monitored more closely for MACE. Routine monitoring of LVEF in asymptomatic patients is not recommended.
Keyphrases
- phase iii
- combination therapy
- open label
- clinical trial
- end stage renal disease
- ejection fraction
- phase ii
- newly diagnosed
- chronic kidney disease
- public health
- peritoneal dialysis
- prognostic factors
- papillary thyroid
- single cell
- double blind
- cell therapy
- squamous cell
- patient reported outcomes
- clinical practice
- mesenchymal stem cells
- young adults
- childhood cancer
- patient reported